Zacks
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
➖
AI Sentiment
Neutral
5/10
- Home
- EDIT
EDIT
Editas Medicine Inc.
as of 12-12-2025 3:45pm EST
$2.55
$0.01
-0.39%
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 233.3M | IPO Year: | 2016 |
| Target Price: | $4.13 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.91 - $4.54 | Next Earning Date: | 11-10-2025 |
| Revenue: | $46,383,000 | Revenue Growth: | -24.90% |
| Revenue Growth (this year): | -36.82% | Revenue Growth (next year): | -33.14% |
AI-Powered EDIT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 74.32%
74.32%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
Burkly Linda
Sell
EVP, CHIEF SCIENTIFIC OFFICER
EDIT Dec 3, 2025
Avg Cost/Share
$2.15
Shares
713
Total Value
$1,535.16
Owned After
68,777
SEC Form 4
Sell
EDIT Dec 3, 2025
Avg Cost/Share
$2.15
Shares
5,603
Total Value
$12,063.82
Owned After
269,087
SEC Form 4
Parison Amy
Sell
SVP, Chief Financial Officer
EDIT Dec 3, 2025
Avg Cost/Share
$2.15
Shares
461
Total Value
$992.58
Owned After
15,908
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Burkly Linda | EDIT | EVP, CHIEF SCIENTIFIC OFFICER | Dec 3, 2025 | Sell | $2.15 | 713 | $1,535.16 | 68,777 | |
| O'Neill Gilmore Neil | EDIT | CEO | Dec 3, 2025 | Sell | $2.15 | 5,603 | $12,063.82 | 269,087 | |
| Parison Amy | EDIT | SVP, Chief Financial Officer | Dec 3, 2025 | Sell | $2.15 | 461 | $992.58 | 15,908 |
Latest Editas Medicine Inc. News
EDIT Breaking Stock News: Dive into EDIT Ticker-Specific Updates for Smart Investing
Compare EDIT vs Leading Stocks
See how EDIT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EDIT Editas Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.